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Leonardo Caporali,5 Francesca Tagliavini,5 Chiara LaMorgia,5,6 Michele Carbonelli,5
Neringa Jurkute,7,8,9,10 Abdelhamid Barakat,4 Philippe Gohier,1 Christophe Verny,1,11
Magalie Barth,12 Vincent Procaccio,1,3 Dominique Bonneau,1,3 Xavier Zanlonghi,13
Isabelle Meunier,14 Nicole Weisschuh,15 Simone Schimpf-Linzenbold,16 Felix Tonagel,17
Ulrich Kellner,18,19 Patrick Yu-Wai-Man,7,8,9,10 Valerio Carelli,5,6 Bernd Wissinger,15
Patrizia Amati-Bonneau,1,3 Pascal Reynier,1,3 European ION Group* and Guy Lenaers1
* For European ION Group members, see Appendix.
Biallelic mutations in ACO2, encoding the mitochondrial aconitase 2, have been identified in individuals with neurodegenerative
syndromes, including infantile cerebellar retinal degeneration and recessive optic neuropathies (locus OPA9). By screening
European cohorts of individuals with genetically unsolved inherited optic neuropathies, we identified 61 cases harbouring variants
in ACO2, among whom 50 carried dominant mutations, emphasizing for the first time the important contribution of ACO2 mono-
allelic pathogenic variants to dominant optic atrophy. Analysis of the ophthalmological and clinical data revealed that recessive
cases are affected more severely than dominant cases, while not significantly earlier. In addition, 27% of the recessive cases and
11% of the dominant cases manifested with extraocular features in addition to optic atrophy. In silico analyses of ACO2 variants
predicted their deleterious impacts on ACO2 biophysical properties. Skin derived fibroblasts from patients harbouring dominant
and recessive ACO2 mutations revealed a reduction of ACO2 abundance and enzymatic activity, and the impairment of the mito-
chondrial respiration using citrate and pyruvate as substrates, while the addition of other Krebs cycle intermediates restored a
normal respiration, suggesting a possible short-cut adaptation of the tricarboxylic citric acid cycle. Analysis of the mitochondrial
genome abundance disclosed a significant reduction of the mitochondrial DNA amount in all ACO2 fibroblasts. Overall, our data
position ACO2 as the third most frequently mutated gene in autosomal inherited optic neuropathies, after OPA1 and WFS1, and
emphasize the crucial involvement of the first steps of the Krebs cycle in the maintenance and survival of retinal ganglion cells.
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Introduction
Mitochondrial diseases represent a group of complex
pathologies affecting several organs, sometimes presenting
with a single symptom, but often combining multiple
symptoms.1 This complexity depends on the dual genetic
contribution of the nuclear and the mitochondrial genome
(mtDNA). To date, mutations in all mitochondrial genes
and in more than 400 nuclear genes have been reported,
sometimes in combinations. In most cases, the mitochon-
drial respiratory chain driving ATP production is
affected, but alterations of alternative mitochondrial
mechanisms as metabolic pathways, protein import and
membrane dynamics have been identified in many dis-
eases, mainly disrupting neuronal physiology.
Aconitase 2 nuclear gene (ACO2; MIM#100850)
encoding the mitochondrial aconitase 2 (ACO2; EC#
4.2.1.3) is involved in the reversible isomerization of
citrate into iso-citrate, through the cis-aconitate intermedi-
ate,2 as part of the second step of the Krebs cycle.
Recessive pathogenic variants in ACO2 were initially
identified in the infantile cerebellar retinal degeneration
syndrome (ICRD, MIM#614559), a severe early-onset
autosomal recessive neurodegenerative condition with
seizures and profound psychomotor retardation related to
progressive cerebral and cerebellar degeneration, and
ophthalmologic abnormalities involving optic nerve and
retinal degeneration.3–7 Additional clinical presentations
related to recessive ACO2 variants were subsequently
reported in individuals with a neuromuscular condition8,9
and syndromic presentations of hereditary spastic para-
plegia8,10,11 (Table 1). Most of these patients presented
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involvement is further highlighted by the identification of
recessive ACO2 mutations in seven individuals from four
independent families that developed isolated optic atrophy
(OPA9; MIM#616289).6,12–14
Inherited optic neuropathies (IONs) are an important
cause of blindness in children and young adults. The
pathological hallmark is the degeneration of the retinal
ganglion cells (RGCs), whose axons converge to form
the optic nerve, allowing the fast transmission of visual
information from the retina to the brain. IONs are
mainly transmitted as a dominant trait as in the case of
Kjer disease or dominant optic atrophy (DOA). In the
majority of cases, DOA is caused by OPA1 mutations,15
and more rarely by pathogenic variants in additional
genes involved in mitochondrial dynamics, including
MFN2, DNM1L, OPA3, AFG3L2 and SPG7,16–21 or in
SSBP1, a gene involved in mtDNA replication.22–24
Recessive ION has also been identified in few individu-
als with isolated recessive optic atrophy (ROA), due to
biallelic mutations in genes involved in the respiratory
complex I assembly and activity, including RTN4IP1,
TMEM126A and NDUFS2,18,25,26 and in WFS1, a gene
involved in calcium transfer and interorganellar interac-
tions between the endoplasmic reticulum and mitochon-
dria.27 In both DOA and ROA cohorts, 10–20% of
individuals with optic atrophy present additional extra-
ocular features, such as sensorineural deafness, periph-
eral neuropathy, encephalopathies, movement disorders
and myopathies.28,29
About 40% of individuals with IONs still do not have a
confirmed molecular diagnosis,30 which prompted us to
screen the ACO2 gene in multicentre patient cohorts to
determine its contribution to the overall disease burden.
Here, we report the identification of 50 index cases carry-
ing heterozygous pathogenic ACO2 variants, together with
11 index cases with biallelic ACO2 mutations. In vitro
and in silico analyses of identified variants confirmed
pathogenicity and deleterious effects on the first steps of
the tricarboxylic citrate acid cycle and on the maintenance
of the mitochondrial genome.
Materials and methods
Consent for genetic investigations
Written informed consent was obtained from each subject
involved in this study or from the parents of subjects
under 18 years of age, according to protocols approved
by the different institutions involved in this study, and in
agreement with the Declaration of Helsinki.
Nomenclature
ACO2 variants are described according to the NCBI
transcript reference sequence NM_001098.2, including 18
exons, encoding a protein of 780 amino acids (reference
sequence NP_001089.1). The numbering of the nucleoti-
des reflects that of the cDNA, as recommended by the
version 2.0 nomenclature of the Human Genome
Variation Society (HGVS): http://varnomen.hgvs.org.31
Molecular genetic analysis
After extraction of genomic DNA from peripheral blood
cells, ACO2 mutations were screened using resequencing
gene panels dedicated to the molecular diagnosis of IONs
or of mitochondrial inherited diseases. Variants were ana-
lysed by applying various prioritization filters described
elsewhere.21,32 All dominant variants were absent or had
minor allele frequency (MAF) threshold of <0.0001 in
the Genome Aggregation Database (gnomAD v.2.1.1,
https://gnomad.broadinstitute.org), while recessive variants
were considered with an MAF threshold <0.005. All can-
didate pathogenic variants were validated by Sanger
Table 1 Pathologies associated to ACO2 dominant and recessive variants, with the number of individuals (ind) and
families (fam) referenced
Pathology Transmission Number of cases reported References
ICRD Recessive 8 ind from 2 fam Spiegel et al.5
3 ind from 2 fam Metodiev et al.6
1 ind Srivastava et al.7
9 ind from 3 fam Sharkia et al.4
1 ind Blackburn et al.8
Neuromuscular Recessive 1 ind Sadat et al.9
1 ind Blackburn et al.8
HSP ‘þ’ Recessive 1 ind Marelli et al.11
11 ind Bouwkamp et al.10
1 ind Blackburn et al.8
Ataxia, dysarthria, dev. delay Recessive 2 ind from 1 fam Blackburn et al.8
ROA Recessive 12 ind from 11 fam This work
2 ind from 1 fam Metodiev et al.6
2 ind from 1 fam Kelman et al.12
1 ind Chen et al.13
2 ind from 1 fam Gibson et al.14
DOA Dominant 66 ind from 50 fam This work
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sequencing, and their segregation assessed in DNA from
relatives, when available.
In silico analysis of ACO2 missense
mutations
The pathogenicity of ACO2 missense variants was
assessed using the SIFT,33 Polyphen-234 and Mutation
Taster35 prediction tools, and splice-site mutations were
analysed by the dbscSNV programme. All variants were
analysed using ACMG rules and classification (https://var
some.com/) (Supplementary Table 1). The impact of
ACO2 missense variants on the protein structure and
function was determined first, by comparing the three-di-
mensional (3D) structure of the native and mutated
ACO2 proteins,36 second, by performing the molecular
dynamics simulation using Gromacs 5.1.4 software to de-
termine the impact of variants on protein stability, amino
acid flexibility and global protein dimension37 and third,
by performing a molecular docking analysis using
Autodock 4.2 to identify the impact of variants on the
interaction between ACO2- [4Fe, 4S] (SF4) clusters and
the interaction of the complex [ACO2-SF4] with the cit-
rate, cis-aconitate and isocitrate ligands.38
Fibroblast analysis
Fibroblasts from the dominant ACO2 P15 patient (c.1253-
1254insA) and the recessive P51 patient (c.36þ 5del;
c.719G>C), as well as from an ICRD patient with biallelic
ACO2 variants (c.487G>A; c.2048G>A), were generated
from skin biopsies and compared throughout the study to
two wild-type fibroblast cell lines. Cells were cultivated in
2/3 Dulbecco’s Minimum Essential Medium (DMEM,
Gibco) supplemented with 1/3 AmnioMAX (Gibco), 10%
foetal calf serum (Lonza) and 1% Penicillin-Streptomycin-
Amphotericin B (Lonza).
Western blotting
Cellular proteins (20 lg) solubilized in Laemmli buffer
were resolved by SDS-polyacrylamide gel electrophoresis
and transferred to polyvinylidene difluoride membranes
(GE Healthcare). For immune-detection, an anti-ACO2
monoclonal antibody (#ab110321, Abcam, 1/1000) was
used. Monoclonal anti-VDAC and anti-a-tubulin antibodies
were used as mitochondrial and cytosolic reference
markers, respectively (Supplementary Fig. 1).
Mitochondrial respiration rates
Mitochondrial oxygen consumption measurements were
performed at 37C and atmospheric pressure using a
high-resolution oxygraph (O2K, Oroboros Instrument,
Innsbruck, Austria).
Respiration rates on permeabilized cells were measured
in respiratory buffer RB (10 mM KH2PO4, 300 mM man-
nitol, 10 mM KCl, 5 mM MgCl2, 0.5 mM EGTA and
1 mg/ml bovine serum albumin, pH 7.2) using different tri-
carboxylic citric acid cycle intermediates and different sub-
strates of CI, CIþCII and CII as followed: First, state 2
(non-phosphorylating) respiration was measured after add-
ing 5 mM citrate. Following the stimulation of the phos-
phorylating respiration by saturating ADP concentration
(1.5 mM), 2.5 mM pyruvate was added, followed by 5 mM
malate. Finally, 5 mM glutamate was added to check
whether the CI-linked maximal phosphorylating respiration
was reached. Succinate (10 mM) was then added to meas-
ure the combined CI and CII-linked respiration with con-
vergent CI þ II electron flow into the Q-junction
corresponding to the maximal stimulated phosphorylating
respiration (OXPHOS capacity). Rotenone (5mM) was
used to inhibit CI activity and thus to obtain the maximal
CII-linked respiration. Oligomycin (F0F1-ATP synthase in-
hibitor, 4mg/ml) and 1mM of the mitochondrial uncoupler
carbonyl cyanide p-trifluoromethoxyphenylhydrazone were
sequentially added to ensure that the cells were fully per-
meabilized. Finally, antimycin A addition (2mg/ml) was
used to check for the non-mitochondrial oxidation.
Enzymatic measurements
The activities of aconitase 2, fumarase and citrate syn-
thase (CS) were measured at 37C with an UVmc2 spec-
trophotometer (SAFAS, Monaco) on the mitochondrial
enriched fraction. Cells were re-suspended in cell buffer
[250 mM saccharose, 20 mM tris(hydroxymethyl)amino-
methane, 2 mM EGTA, 1 mg/ml bovine serum albumin,
pH 7.2; 50 ll/106 cells], disrupted by two freezing-thaw-
ing cycles, washed, centrifuged for 1 min at 16 000 g to
eliminate the cytosolic fraction and re-suspended in the
cell buffer (125 ll/106 cells). Aconitase activity was imme-
diately assayed according to39 in Tris-HCl buffer
(50 mM, pH 7.4) supplemented with 0.5 mM MnAcetate
and containing 0.1% Triton-X100. One hundred millimo-
lar isocitrate were used to initiate the reaction and cis-
aconitate production was followed at 240 nm. Fumarase
activity was measured in KH2PO4 buffer (50 mM, pH
7.4) supplemented with 0.1 mM EDTA and containing
0.1% Triton-X100. Ten millimolar malate was used to
initiate the reaction and fumarate production was fol-
lowed at 250 nm. CS activity was assayed by a standard
procedure.40 The protein content was determined with
the bicinchoninic assay kit (Uptima, Interchim,
Montluçon, France) using bovine serum albumin as
standard. Aconitase 2 activity was normalized to fumar-
ase and CS as mitochondrial content markers. Enzymatic
measurements were performed at least twice in duplicate,
on two different cell pellets from different passages.
Quantification of mtDNA copy
number
For mtDNA quantification, total DNA was isolated from
fibroblasts by using a High Pure PCR Template Preparation
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Kit (Roche ref 11796828001). Q-PCRs were performed in
triplicate in 96-well reaction plates (Applied Biosystems).
Each reaction (final volume 10ml) contained 25 ng DNA,
5ml of Power SYBR-Green PCR Master Mix (Applied
Biosystems) and 0.5mM of each forward and reverse pri-
mer. COX1 and MT-ND4, mitochondrial encoded genes,
were amplified and b2 microglobulin (b2 m) and GAPDH
nuclear-encoded genes were used as a normalizing control.
Primers were COX1: F-50-TCCACTATGTCCTATCAATA-
30 and R-50-GGTGTAGCCTGAGAATAG-30; ND4: F-50-
CGCACTAATTTACACTCA-30 and R-50-GCTAGTCATAT
TAAGTTGTTG-30; b2m: F-50-CAGCTCTAACATGATAA




Molecular data concerning the mutation types (Fig. 1)
and clinical data, including age at diagnosis, visual acuity
and segment of atrophy of the optic nerve (Fig. 2) were
statistically compared between the dominant and recessive
cases, using the Fisher exact test.
Biochemical data generated from the analysis of the
mitochondrial respiration parameters, mtDNA amounts
and protein abundancies were statistically compared
between the dominant, recessive, ICRD and control
samples, using the two-tailed paired t-test.
All data from this work are available upon request.
Results
Identification of ACO2 variants in
individuals with ION
Cohorts including about 1000 molecularly undiagnosed
ION individuals from France, Germany, Italy, Spain,
Belgium and the UK were screened by targeted sequenc-
ing for the presence of ACO2 variants. Among individu-
als with a single ACO2 variant, we selected cases with
an MAF lower than 0.0001, whereas in individuals with
biallelic heterozygous composite or homozygous variants,
we selected the cases with an MAF lower than 0.005 for
each variant. This led to the identification of 50 individu-
als harbouring 1 of 43 different heterozygous mutations,
among which 29 were novel, as well as 11 individuals
with biallelic mutations, among which 8 were novel. A
compilation of these variants and the associated amino
acid changes are displayed on ACO2 primary sequence
and 3D structure in Fig. 1A and C and listed in the
Supplementary Table 1. Notably, four dominant variants
p.(Arg474Gly), p.(Trp603Ser), p.(Ser669Leu) and
p.(Arg671Trp) were identified in two unrelated individu-
als and p.(Arg671Gln) in four unrelated individuals,
while one recessive variant, p.(Leu74Val), with an MAF
value of 0.00369, was found in five unrelated ROA
individuals, and also formerly described in eight individu-
als with syndromic ACO2 presentations. This
p.(Leu74Val) variant was associated once with
p.(Gly661Arg) in the P56 individual, a combination al-
ready reported in an ROA family.6 Segregation analysis
was performed where available. In DOA cases, all
affected relatives carried the variant, whereas some rela-
tives in the families of patients P6, P8, P9, P13 and P33
carrying the variant were asymptomatic, as occasionally
observed in families with OPA1 mutations.15,41
Moreover, segregation analysis revealed de novo muta-
tions in the P15 and P18 index cases.
Analysis of the types of mutations identified in ACO2
(Fig. 1B) revealed that two-third of all variants were mis-
sense mutations, irrespective of the dominant or recessive
mode of inheritance, while nonsense, frame-shift, splice-
site mutations and deletions accounted together for the
third part of all mutations identified, without significant
difference between the distribution of the mutation types
between dominant and recessive cases (P-value: 0.80).
Notably, the identification of null alleles in dominant
cases suggests that ACO2 haploinsufficiency contributes
mainly to DOA pathophysiology.
Clinical examination of individuals
with ACO2 mutations
All individuals harbouring ACO2 mutations had an oph-
thalmological examination. Optic atrophy was identified
by fundus examination and confirmed by optical coher-
ence tomography, which showed decreased retinal nerve
fibre layer thickness (Fig. 2A and B). Additional ophthal-
mological features are summarized in Supplementary
Table 1 and Fig. 2C. Age at first diagnosis of optic atro-
phy symptoms occurred essentially during the first two
decades, without significant difference between dominant
and recessive cases (P-value: 0.54; Fig. 2C). The distribu-
tion of the visual acuity from all eyes revealed that the
recessive cases were significantly (P-value: 0.001) more
severely affected than the dominant ones, with more than
60% of eyes from the ROA group having a visual acuity
lower than 0.1, whereas more than 80% of eyes from
the DOA group have a visual acuity above 0.1 (Fig. 2D).
Analysis of the optic disc by optical coherence tomog-
raphy and retinal nerve fibre layer thickness measure-
ments indicate a preferential involvement of the temporal
quadrant in both the dominant and recessive patient
groups (Fig. 2E), suggesting a similar pattern of RGC de-
generation, irrespective of the mode of transmission (P-
value: 0.88). Assessment of colour vision revealed highly
divergent alterations, including protan, deutan and tritan
types of dyschromatopsy (data not shown). Notably,
eight patients with DOA or ROA showed additional ret-
inal alterations, including macular microcysts and a
macular dystrophy in one case. In 6/50 (12%) of the
dominant cases and 3/11 (27%) of the recessive cases,
additional extraocular symptoms were found in addition
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to optic atrophy, with a single case showing hearing loss
(P38) and two cases showing a late-onset cerebellar
ataxia (P19 and P53).
Evaluating the pathogenicity of
ACO2 variants
In silico analysis was performed in order to ascertain the
pathogenicity of identified ACO2 variants. Each variant
was evaluated by using Sift, Polyphen-2 and Mutation
Taster prediction tools (Supplementary Table 1). All dom-
inant variants, with the exception of the c.1454A>G
[p.(Glu485Gly), P23] and c.1898G>A [p.(Arg633His),
P32], were predicted to be either deleterious or disease
causing by all three software. Similarly, the ACMG clas-
sification tool predicted that 19 were pathogenic (class
5), 10 likely pathogenic (class 4) and 13 with uncertain
significance (class 3). Prediction results were less clear-cut
regarding the recessive variants, with five classified as
pathogenic (class 5), six likely pathogenic (class 4) and
five with uncertain significance (class 3), suggesting
that they might have milder effect on the protein activity.
The seven variants affecting splice-sites were predicted to
be deleterious by the dbscSNV tool, while only five
affecting the 61 or 62 splicing position were classified
as pathogenic, and two affecting the þ5 position as of
uncertain significance according to the ACMG rules
(Supplementary Table 1).
To gain further insights on the effects of the missense
variants on the ACO2 biophysical properties, we ana-
lysed each variant in silico using three sets of predictive
tools. To infer the 3D structure of the human ACO2 pro-
tein, the 780 amino acids of the human sequence were
aligned and positioned on the 3D crystal structure of the
Sus scrofa ACO2 protein42 using the SwissModel server.
Then, the ACO2 3D structure was modified with the
PyMOL software to visualize all mutated proteins and
minimized using the GROMACS software. Comparison
of native and mutated ACO2 proteins showed that all
variants affect the 3D structure by acquiring and/or los-
ing hydrogen bonds and/or hydrophobic interactions,








































































































































































































































































































































































Figure 1 Localization and quantification of the ACO2 variants on the protein primary structure. (A) The structure of the ACO2
protein including the different functional domains is represented, with all the dominant mutations identified shown on top, and all the recessive
mutations identified shown below (different colours according to the type of variant), interspersed with the published recessive variants
(in black). The number of times that a variant has been identified is indicated between brackets. (B) Representation of the different variant
subtypes affecting ACO2 in all optic atrophy cases (left), in dominant cases (right top) and in recessive cases (right bottom). There are no
significant differences (P-value: 0.80) between dominant and recessive groups. (C) Three-dimensional structure of ACO2 protein showing the
dominant (red) and recessive (magenta) variants and the ligands localization. [4Fe, 4S] cluster (cyan), citrate (green), cis-aconitate (blue) and
isocitrate (yellow).
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p.(Gly431Ser), and the recessive p.(Gly240Ala) and
p.(Val761Met) variants. Results of the molecular dynamic
simulation revealed that all variants increased protein sta-
bility (RMSD), with the exception of the dominant
p.(Val247Ala) variant, which decreased protein stability,
and the dominant p.(Ile172Leu) and the recessive
p.(Arg56Cys) variants, which displayed no change in pro-
tein stability. All variants were affected for the amino
acid flexibility parameter (RMSF), and all had decreased
protein dimension (Rg) except the dominant
p.(Ile172Leu) and p.(Val247Ala) variants and the reces-
sive p.(Arg56Cys) variants, which displayed a normal
protein dimension. Molecular docking analysis of the na-
tive and mutated proteins complexed to the iron-sulphur
cluster [ACO2-SF4] did not evidence a significant differ-
ence of their binding energy (3.43 kcal/mol for the na-
tive ACO2 and from 3.81 to 3.38 kcal/mol for
mutated proteins). All variants had also normal binding
energies for citrate, isocitrate and cis-aconitate, with the
exception of the dominant p.(Ser669Leu), p.(Arg671Gln),
p.(Arg671Trp), p.(Gly703Arg) and p.(Ala710Pro) variants
that displayed increased binding energy and/or alteration
of the substrate binding to the SF4 complex (see
Supplementary Table 2). Altogether, these in silico analy-
ses reveal that all ACO2 variants display altered biophys-
ical properties, although our results did not identify a
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Figure 2 Clinical data of the dominant and recessive ACO2 individuals. (A and B) Left: Eye fundus pictures of individuals with a
dominant (A: P8) and a recessive (B: P52) ACO2 mutation revealing the temporal pallor of the optic discs in both REs and LEs. Right: Evaluation of
the retinal nerve fibre layer by optic coherence tomography in the same individuals, disclosing in both cases the retinal nerve fibre layer
reduction in the temporal quadrants. The green area defines the 5th to 95th, the yellow area the 1st to 5th and the red area below the 1st
percentiles. INF ¼ inferior quadrants; LE ¼ left eye; NAS ¼ nasal; RE ¼ right eye; SUP ¼ superior; TEMP ¼ temporal. (C) Ages at diagnosis
categorized in six groups and represented as percentages of the number of individuals in the dominant and recessive cohorts (y ¼ years) are not
significantly different (P-value: 0.54). (D) Visual acuities (VA), categorized in five ranges, and represented as percentages of the total number of
eyes are significantly different between dominant and recessive cases (P-value: 0.001). (E) Alterations of the optic disc, according to the different
retinal nerve fibre layer quadrants were assessed by optical coherence tomography. Data are represented as percentages of each alteration from
all eyes for which the data were available. (temp. ¼ temporal; inf. ¼ inferior; sup. ¼ superior) and are not significantly different between
dominant and recessive cases (P-value: 0.88). (F) Percentage of dominant and recessive ACO2 individuals presenting extra-ocular symptoms.
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ACO2 mutated fibroblasts show
reduced ACO2 abundance and
activity, with alterations in the first
steps of the Krebs cycle and depletion
of mtDNA copy number
In order to analyse the effects of dominant and recessive
ACO2 variants on the mitochondrial physiology, we gen-
erated skin fibroblasts from a DOA (P15) and an ROA
(P51) patient, as well as from an ICRD patient carrying
the c.487G>A/p.(Val163Met) and c.2048G>A/
p.(Gly683Asn) variants. All cells displayed a normal
growth in standard culture media, compared to controls
(not shown). Western blot analysis revealed that ACO2
amounts were similarly reduced by half in the three
mutated ACO2 cell lines (Fig. 3A), while the CS
remained unchanged, witnessing a regular amount of
mitochondria in all cell lines (Fig. 3B). Assessment of the
mitochondrial aconitase activity, relatively to the CS or
the fumarase activity, disclosed a 50% decrease in both
dominant and recessive backgrounds, whereas the activity
was drastically reduced in the ICRD cell line (Fig. 3C
and D). Assessment of mitochondrial oxygen consump-
tion in the maximal phosphorylation condition from
permeabilized fibroblasts, in the presence of citrate as the
sole substrate evidenced a significant reduction of the
respiration rate in the three mutated cell lines, which was
more severe in the ICRD cell line. Addition of pyruvate
stimulated the respiration by the production of one
NADH related to the pyruvate to acetyl-coA reaction,
but to a lower level in all ACO2 cell lines compared to
wild-type cells, with values remaining significant for the
recessive ACO2 and ICRD cells (Fig. 3E). Further add-
ition of malate restored the respiration up to the level of
the wild-type cell lines, and the subsequent CI-linked
respiration with maximal substrate supply (pyruvate,
malate, glutamate), or CI þ CII-linked respiration (suc-
cessive addition of succinate) were maintained to levels
comparable to the wild-type cell lines, suggesting that an
adaptation process by-passes the Krebs cycle bottleneck
due to the reduced ACO2 activity. Finally, the CII-linked
respiration did not significantly differ between the DOA
and ROA cell lines, compared to controls, but was
decreased for the ICRD cell line (Fig. 3E), witnessing a
normal FADH2 production and complex II activity in
both DOA and ROA. Further evaluation of the enzymat-
ic activities of the respiratory complexes I to V did not
reveal any significant difference in comparison with con-
trols, irrespective of the ACO2 genotype (Fig. 3F).
Measurements of mtDNA abundance in the three ACO2
mutated cell lines disclosed a significant reduction of
more than 50% in the three mutated cell lines compared
to the control cells (Fig. 3G), as already reported for cells
lacking the mitochondrial aconitase activity.9 Further
evaluation of the mitochondrial network shape did not
reveal modification of the fusion–fission ratio in the dom-
inant and recessive ACO2 cells (data not shown).
Altogether, these data indicate that the ACO2 domin-
ant and recessive mutations affect significantly the mito-
chondrial aconitase activity and consequently the first
steps of the Krebs cycle and the pyruvate/citrate depend-
ent respiration, with a further depletion of the mitochon-
drial genome. Nevertheless, they also indicate that the
mitochondrial respiration based on alternative Krebs cycle
substrates can be restored to a normal level, by circum-
venting the metabolic bottleneck due to ACO2 deficiency
in both DOA and ROA genetic backgrounds.
Discussion
IONs are genetically heterogeneous, and reaching a con-
firmed molecular diagnosis can be challenging. In order
to improve diagnostic pathways, we have screened large
cohorts of European individuals with molecularly undiag-
nosed optic neuropathy to determine whether ACO2 var-
iants account for a proportion of cases. In addition to
the seven ION cases that were found to harbour recessive
ACO2 mutations as previously described,6,12–14 this study
highlights, for the first time, the important contribution
of mono-allelic ACO2 variants as a cause of isolated
optic atrophy, with 50 independent cases carrying domin-
ant pathogenic variants. Clearly, both dominant and re-
cessive mutations in ACO2 can cause the very same
ophthalmological presentation with a pathological predi-
lection for RGCs within the inner retina. Analyses of the
clinical data indicate that ACO2 mutations result in oph-
thalmological and optical coherence tomography features
similar to those seen in the context of OPA1 muta-
tions,15,43 with the preferential involvement of the papil-
lomacular bundle. There was variable disease severity
with visual acuity ranging from normal in clinically
asymptomatic individuals to severe visual impairment
meeting the criteria for legal blindness. The age at which
the diagnosis was first made mainly occurred during the
first two decades of life in both dominant and recessive
individuals. Notably, in 8 out of the 61 individuals with
ACO2 mutations mild retinal alterations, including macu-
lar microcysts and macular dystrophy, were noticed.
While macular microcysts are a non-specific retinal alter-
ation, possibly of mechanical origin, also reported in
severely affected DOA and Leber Hereditary Optic
Neuropathy cases,44,45 macular dystrophy, a truly degen-
erative process, converges with the retinal features
described in ICRD and other syndromic clinical presenta-
tions related to ACO2 recessive variants.6,10,46 In add-
ition, 12% of dominant and 27% of recessive cases
displayed extraocular symptoms that can either be inci-
dentally related to the ACO2 individuals, or as in OPA1
cases, related to highly specific mutations. This could
also be the consequence of ageing with an ACO2
mutated genetic background, as individuals P19 aged 73
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and P53 aged 61 both showed cerebellar related symp-
toms, mirroring a late-onset ICRD condition. Thus, al-
though the ACO2 dominant and recessive presentations
that we identified are clinically similar, disclosing in most
cases an isolated optic atrophy, the recessive cases do ap-
pear more severely affected than the dominant ones,
suggesting that the combination of bi-allelic ACO2 var-
iants compromise to a higher level the aconitase 2
functions.
Concerning the dominant cases, we have identified
43 variants, among which 30 have not been referenced
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Figure 3 Analysis of dominant and recessive ACO2 mutated fibroblasts, compared to an ACO2-related ICRD fibroblast
cell line. All experiments were performed at least in two independent replicates for each control (ctr.) and dominant (dom.) and recessive (rec.)
ACO2 fibroblasts, and compared to one ACO2-related ICRD fibroblast cell line (ICRD). Results are mean 6 SD. Statistical analysis of results from
all the following experiments was performed using the two-tailed paired t-test. (A) Western blots with antibodies against ACO2 and VDAC
proteins. The quantification of the relative ratio shows a significant decrease of ACO2 protein in all patient fibroblasts (*P-value <0.05). (B) CS
activity is not affected by ACO2 mutations. (C and D) Relative ACO2 activity normalized to the CS (C) and to the fumarase (D) activities shows a
tendency to decrease in the dominant and recessive ACO2 fibroblasts, and a significant decrease in the ICRD fibroblasts (*P-value <0.05).
(E) The assessment of fibroblast respiration (mitochondrial oxygen rates related to maximal phosphorylation condition in permeablized
fibroblasts) by oxygraphy, using the Krebs cycle substrates, Citrate (C), pyruvate (P), malate (M), glutamate (G), succinate (S), followed by the
inhibition of complex I by rotenone (R), show that the respiration related to the use of citrate is decreased in all ACO2 fibroblasts, partially
increased by pyruvate, and fully restored by malate. Further stimulation by glutamate and succinate is limited, and only the ICRD fibroblasts are
significantly more affected than the other fibroblasts by the Rotenone (*P-value <0.05). (F) Enzymatic activities from four independent
experiments of the respiratory complexes (CI to CV) from the control and the ACO2 mutated fibroblast strains related to the CS enzymatic
activity did not reveal a significant difference between control and mutated fibroblasts. (G) Mitochondrial DNA copy number in ACO2 mutated
fibroblasts normalized to control fibroblasts reveals a significant decrease in the mitochondrial genome in all ACO2 cells (*P-value <0.05).
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missense changes that are predicted to be pathogenic,
with the exception of the p.(Glu485Gly) and
p.(Arg633His) amino acid changes that were identified in
individuals (P23 and P32, respectively) with an asymmet-
ric optic atrophy. The remaining third of the variants are
essentially nonsense, frame-shift and splice mutations,
most probably behaving as null alleles. This suggests that
haploinsufficiency in ACO2 activity is the basic patho-
physiological mechanism that drives RGC loss and optic
nerve degeneration secondary to ACO2 mutations, simi-
larly to what is observed in OPA1 cases. This should
prompt an in-depth ophthalmological examination of
parents of the recessive ACO2 patients carrying such null
alleles.
Regarding the recessive cases, among the 11 individuals
with bi-allelic ACO2 mutations, we identified eight novel
variants, including three missense, three splice-site, one
frame-shift, and one nonsense mutations. We also identi-
fied five individuals harbouring the previously reported
p.(Leu74Val) variant which is the disease-associated vari-
ant most frequently observed in population databases
(MAF ¼ 0.00369). The p.(Leu74Val) variant was found
in combination with the p.(Gly661Arg) variant in one in-
dividual, a genotype previously described in an ROA pa-
tient.6 For the four other individuals, the p.(Leu74Val)
variant was combined with splice site and nonsense
mutations, therefore, suggesting that the p.(Leu74Val)
amino acid change has a mild effect on ACO2 function.
This also applies for the p.(Gly240Ala) variant in patient
P51, since this allele is associated with a splice-site muta-
tion identified in our ROA cohort. Otherwise, all other
recessive individuals displayed a combination of missense
mutations that were never reported in any other ACO2
associated clinical phenotype. Notably, the in silico ana-
lysis of all recessive missense mutations using the Sift,
PolyPhen-2 and Mutation Taster software disclosed a
combination of one variant with predicted pathogenicity
with a second variant of less clear-cut pathogenicity in
compound heterozygous individuals. Conversely, the two
homozygous variants p.(Arg56Cys) and p.(Pro227His),
identified in patients P52 and P55, respectively, were pre-
dicted to be deleterious and likely pathogenic, requiring
further analyses to decipher their respective effects on
ACO2 functions.
Additional biophysical analyses of the changes in the
structure, in the molecular dynamics and the protein–lig-
and interactions of the missense mutated proteins
revealed that all mutated proteins were altered with at
least one out of the set of three criteria investigated,
being affected. Nevertheless, none of these criteria could
discriminate between dominant and recessive variants.
However, some dominant variants affecting the ACO2
catalytic site located between the 669 and 710 amino
acid positions, showed a clear alteration of the energy
binding with aconitase substrates, emphasizing their key
role for the aconitase enzymatic activity.
The functional consequences of the dominant and re-
cessive ACO2 variants identified in our study were
probed further in patient-derived skin fibroblasts. As al-
ready observed for ROA individuals with biallelic ACO2
mutations,5,46 the aconitase abundance and activity were
reduced by half both in recessive and dominant cell lines,
suggesting a common pathophysiological mechanism
related to ACO2 mutations irrespective of the mode of
inheritance. This had a significant consequence on the
oxidative process when using citrate and pyruvate sub-
strates, with the first steps of the Krebs cycle being sig-
nificantly impaired by the reduced aconitase activity, thus
leading to a metabolic bottleneck for the OXPHOS pro-
cess. Nevertheless, the addition of substrates involved
downstream of the ACO2 step, restored a normal
OXPHOS respiration, suggesting that the production of
NADH and FADH2 is compensated by the reactions
occurring downstream of isocitrate production. This fur-
ther suggests that the mitochondrial respiratory chain
complexes are intact in these cells given that no alteration
of the maximal enzymatic activity of complexes I to V
was observed, irrespective of the ACO2 genetic back-
ground. Finally, similarly to what was already reported
in other models and cellular conditions,9 we observed a
significant depletion of the mtDNA, reinforcing the role
of ACO2, or of its substrates, in the maintenance of the
mitochondrial genome. This in the context of fibroblasts
apparently did not impinge directly on the OXPHOS
setup, however, most probably may become relevant in
high energy-dependent tissues and cell types, in particular
in RGCs. In fact, the partial but consistent reduction in
mtDNA copy number provides an interesting link to the
pathophysiological mechanism recently discovered in the
SSBP1-related DOA, for which the instability of the mito-
chondrial genome is the primary alteration responsible
for the disease.22,24 Congruently, as for the SSBP1-mutant
patients, from the clinical standpoint in addition to optic
atrophy, some retinal symptoms may also occur, such as
peculiar retinal dystrophic changes.22–24
In conclusion, our study highlights the importance of
dominant and recessive ACO2 mutations in patients with
isolated or syndromic optic atrophy phenotypes.
Dominant mutations are far more frequent than recessive
ones at least in European populations, placing ACO2 as
the third most frequent genetic cause of IONs, after
OPA1 and WFS1. This also adds a new pathophysio-
logical pathway involving mitochondria, as responsible
for RGC degeneration, after the alterations of the mito-
chondrial dynamics in DOA and of the complex I assem-
bly in ROA, connecting the first steps of the Krebs cycle
to the OXPHOS respiration and the maintenance of the
mitochondrial genome integrity. The next challenge is to
investigate the underlying pathophysiological mechanisms
in greater detail, to develop potential therapeutic inter-
ventions that will promote RGC survival in the presence
of ACO2 mutations.
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